BHC (Bausch Health) Long-Term Debt: $19,875 Mil (As of Mar. 2026)


BHC Bausch Health Companies Inc BHC
58 GF Score
Price $4.77
GF Value $7.56
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Bausch Health Long-Term Debt?

Bausch Health BHC -3.25% 58 Long-Term Debt is $19,875 Mil as of Mar. 2026. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.56 (Possible Value Trap). The stock has 3 warning signs investors should review.

Bausch Health's Long-Term Debt for the quarter that ended in Mar. 2026 was $19,875 Mil.

Bausch Health's quarterly Long-Term Debt increased from Sep. 2025 ($20,463 Mil) to Dec. 2025 ($20,592 Mil) but then declined from Dec. 2025 ($20,592 Mil) to Mar. 2026 ($19,875 Mil).

Bausch Health's annual Long-Term Debt declined from Dec. 2023 ($21,938 Mil) to Dec. 2024 ($18,942 Mil) but then increased from Dec. 2024 ($18,942 Mil) to Dec. 2025 ($20,592 Mil).

Bausch Health  (NYSE:BHC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Bausch Health Long-Term Debt Related Terms

Bausch Health Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Bausch Health's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health Long-Term Debt Chart

Bausch Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22,654.00 20,334.00 21,938.00 18,942.00 20,592.00

Bausch Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21,228.00 20,859.00 20,463.00 20,592.00 19,875.00
BHC
58GF Score
Bausch Health Companies Inc BHC
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $19,875 Mil mean?
Bausch Health (BHC) has a Long-Term Debt of $19,875 Mil as of Mar. 2026.
Is Bausch Health's Long-Term Debt too high?
Bausch Health's current Long-Term Debt is $19,875 Mil. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Long-Term Debt compare to ZTS and UTHR?
Bausch Health's Long-Term Debt of $19,875 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Bausch Health's current Long-Term Debt is $19,875 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Possible Value Trap. The stock's GF Value™ is $7.56, compared to a current price of $4.77 — trading 36.9% below its estimated fair value. The current Long-Term Debt is $19,875 Mil. Bausch Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Bausch Health (BHC), the current Long-Term Debt is $19,875 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (BHC) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of $4.77 is trading 36.9% below its estimated GF Value™ of $7.56. GuruFocus considers Bausch Health to be Possible Value Trap.

Key valuation signals for BHC:

  • Long-Term Debt: $19,875 Mil
  • GF Value™: $7.56 vs. price of $4.77 (36.9% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score

Get the complete analysis for BHC

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.77
Price
$7.56
GF Value